Ginkgo Bioworks Quarterly Cash Flow Statement
NYSE: DNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ginkgo Bioworks free cash flow
In the quarter ended Jun 30, 2026, Ginkgo Bioworks generated -$44.3 million of operating cash flow and spent $2.6 million on capital expenditures. That left free cash flow of -$46.9 million, a free-cash-flow margin of -232.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Ginkgo Bioworks cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -46.71M | -82.59M | -80.75M | -80.75M | -60.30M | -90.96M | -107.53M | -56.40M | -217.18M | -165.91M | -211.69M | -302.89M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 12.31M | 12.80M | 13.66M | 15.26M | 15.25M | 14.82M | 15.65M | 17.17M | 17.33M | 12.87M | 12.84M | 21.06M |
| Stock-Based Compensation | 7.59M | 15.85M | 21.03M | 24.33M | 18.80M | 17.39M | 20.56M | 13.86M | 37.15M | 40.78M | 42.84M | 52.57M |
| Change in Working Capital | -6.02M | 3.08M | -12.18M | -2.08M | -10.41M | -14.44M | 7.11M | -54.05M | -7.82M | -8.53M | 19.28M | -769.00K |
| Operating Cash Flow | -44.27M | -46.69M | -47.68M | -31.61M | -40.25M | -51.52M | -42.44M | -103.50M | -84.39M | -89.26M | -57.83M | -73.55M |
| Capital Expenditures | -2.62M | -1.93M | -5.00K | 0 | -38.00K | -7.62M | -13.71M | -15.09M | -27.03M | -6.71M | -3.45M | -4.38M |
| Investing Cash Flow | 11.09M | 23.13M | 95.10M | -72.82M | -63.89M | -198.68M | -13.09M | -10.20M | -26.84M | -12.11M | -46.67M | -3.38M |
| Financing Cash Flow | 16.49M | -19.00K | 8.14M | 9.94M | -98.00K | -207.00K | -203.00K | -465.00K | -226.00K | -845.00K | -632.00K | -315.00K |
| Net Change in Cash | -16.65M | -23.70M | 55.41M | -94.39M | -104.05M | -250.34M | -55.80M | -114.20M | -111.47M | -102.37M | -105.03M | -77.44M |
| Free Cash Flow | -46.89M | -48.62M | -47.68M | -31.61M | -40.29M | -59.14M | -56.15M | -118.59M | -111.42M | -95.97M | -61.28M | -77.93M |
This table shows 12 quarterly periods of Ginkgo Bioworks's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow DNA's reporting calendar. What is a cash flow statement?